Skip to main content Skip to search

ABOUT US

Iconnectar was founded in 2019 with the aim of delivering breakthrough medicines for patients. Our innovative programs are based on foundational science and benefit from the exceptional innovation with world-class collaborators. Our goal is to create innovative medicines that are disease modifying and satisfy significant unmet medical need. To achieve this goal on cost and time efficiency, Iconnectar runs a virtual R&D operating model that seeks innovation through the best academic and business partners.

LEADERSHIP TEAM

Pathik Brahmkshatriya, Ph.D.

Chief Executive Officer

As CEO of Iconnectar Pharma Innovations, Pathik brings extensive experience in the field of early stage drug discovery and development.

Pathik worked as Group Leader at Oxygen Healthcare (O2h) where he managed and directed a work force of almost 45 scientists working on FTE, FFS and risk-share projects. At O2h, he led >35 projects working with clients based out of USA, UK, Europe and Asia ranging from large pharma, biotechs, virtual companies and academic groups. He also served as lead computational chemist and helping advance some of the early stage in-house programs.

Pathik's last assignment was to lead NCE discovery program at Kashiv BioSciences managing cross-functional discovery projects where he has been a key contributor right from inception of the project on several therapeutic areas like pain, oncology, CNS disorders and orphan diseases; of which an oncology program successfully entered into IND-enabling studies in a very short time span. In a virtual environment, he worked with almost all the premier CROs across India and many across the globe. He also supported due diligence activities for both in-licensing and out-licensing opportunities.

Pathik received a Ph.D. in Medicinal Chemistry in the area of cardiovascular diseases; and Postdoc in the field of in silico drug design from Institute of Organic Chemistry and Biochemistry, Prague. He has received several awards in his career from agencies like CSIR, INSA, GUJCOST, European Atherosclerosis Society (EAS), and World Academy of Science, Engineering and Technology (WASET). He has co-authored over 30 peer-reviewed publications, patents, abstracts and book chapters and has presented at several international conferences.